Syndax Pharmaceuticals
SNDX
71 hedge funds and large institutions have $160M invested in Syndax Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 32 increasing their positions, 13 reducing their positions, and 7 closing their positions.
146% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 13
79% more capital invested
Capital invested by funds: $89.1M → $160M (+$70.8M)
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
50% more call options, than puts
Call options by funds: $929K | Put options by funds: $621K
3% more funds holding
Funds holding: 69 → 71 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.5% less ownership
Funds ownership: 67.88% → 63.37% (-4.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.34M |
| 2 |
Renaissance Technologies
New York
|
+$855K |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$796K |
| 4 |
State Street
Boston,
Massachusetts
|
+$595K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$589K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$1.62M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$753K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$569K |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$547K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$519K |
SNDX Hedge Fund Activity: Q2 2019 in Review
71 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q2 2019, worth a combined $160M — up 79% from $89.1M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new SNDX positions and 7 closed out — a net gain of 4 holders — while 32 added to existing stakes and 13 trimmed.
The largest buyer was BlackRock, adding an estimated $1.34M. The largest seller was BVF Inc, cutting an estimated $1.62M.
- 71 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q2 2019, up from 69 in Q1 2019.
- Funds reported $160M of Syndax Pharmaceuticals stock for Q2 2019, up 79% quarter-over-quarter.
- 11 funds opened new Syndax Pharmaceuticals positions in Q2 2019 and 7 closed out, a net change of +4 holders.
- The largest Syndax Pharmaceuticals buyer in Q2 2019 was BlackRock, an estimated $1.34M added.
- The largest Syndax Pharmaceuticals seller in Q2 2019 was BVF Inc, an estimated $1.62M sold.
Based on aggregated 13F filings for Q2 2019.